Formic Acid

Formic Acid

SCHEMBL5085564

Cc1ccccc1CNC(=O)C1CC1.O=CO

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.54
MAPT P10636 3/20 0.54
CA12 O43570 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
CA9 Q16790 1/20 0.54
EPHX2 P34913 1/20 0.54
HPGD P15428 4/20 0.53
KMT2A Q03164 2/20 0.52
ALDH1A1 P00352 2/20 0.51
GAA P10253 1/20 0.51
LMNA P02545 2/20 0.50
TP53 P04637 2/20 0.50
POLB P06746 2/20 0.50
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
HTT P42858 1/20 0.48
USP2 O75604 1/20 0.48
RXFP1 Q9HBX9 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5071517 0.94 P2RX7 (0.59) P2RX7MAPTCA12CA1CA2
Formic Acid SCHEMBL5082573 0.86 RXFP1 (0.53) ALDH1A1GAATP53RXFP1
SCHEMBL13746180 0.84 CHRM1 (0.59) P2RX7MAPTCA12CA1CA2
Formic Acid SCHEMBL5073526 0.84 ALDH1A1 (0.60) P2RX7EPHX2HPGDKMT2AALDH1A1
SCHEMBL13745561 0.83 EPHX2 (0.60) P2RX7MAPTCA12CA1CA2
Formic Acid SCHEMBL5072983 0.82 P2RX7 (0.52) P2RX7MAPTEPHX2HPGDKMT2A
Formic Acid SCHEMBL5082474 0.82 PKM (0.60) MAPTHPGDKMT2AALDH1A1LMNA
SCHEMBL5358064 0.81 LMNA (0.57) P2RX7MAPTCA12CA1CA2
SCHEMBL5311961 0.79 P2RX7 (0.52) P2RX7EPHX2HPGDALDH1A1GAA
SCHEMBL10114144 0.79 CA12 (0.52) P2RX7MAPTCA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312242-A1 7-ARYL-3, 9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES ACTELION PHARMACEUTICALS, LTD. (CH) 2008-12-18 US disclosed
US-20050176700-A1 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases ACTELION PHARMACEUTICALS LTD. (CH) 2005-08-11 US disclosed
EP-1501830-A1 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES Actelion Pharmaceuticals Ltd. (CH) 2005-02-02 EP disclosed
WO-2003093267-A1 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES ACTELION PHARMACEUTICALS LTD (CH) 2003-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176700-A1 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases REN, AGTR1, ACE P2RX7 737/4885MAPT 4578/4885CA12 4756/4885
US-20080312242-A1 7-ARYL-3, 9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES REN, AGTR1, ACE P2RX7 737/4885MAPT 4578/4885CA12 4756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.